Envista Holdings Corp (NVST)

NYSE · Healthcare · Medical Instruments & Supplies · USA

Envista Holdings Corp is a mid cap company (market value between $2 billion and $10 billion) in the Medical Instruments & Supplies industry.

Envista is a global dental products company comprising multiple brands including Nobel Biocare, Ormco, DEXIS, and Kerr. It develops and markets dental implants, orthodontic solutions, digital imaging systems, and consumable products serving dental professionals worldwide through direct sales and distribution partners across two segments: Specialty Products & Technologies and Equipment & Consumables.

From its FY2025 annual report (Form 10-K)

Intrinsic value, DCF valuation, financial health and value investing analysis for the Envista Holdings Corp stock.

Our verdict on NVST

Slightly undervalued: intrinsic value $29.12 per share, market price $23.70, margin of safety 18.6% (as of 2026-11-17).

Discounting its cash flows at 8.5% (average of 3 methods) values the shares at $29.12; the price of $23.70 is 19% below that value, and 77% of that value comes from beyond year five.

ETFs with the most weight in NVST

17 more funds hold it; the full list is part of the paid plan.

More on NVST

Browse

Peers in Medical Instruments & Supplies

All 52 Medical Instruments & Supplies stocks

Cheaper than NVST in Medical Instruments & Supplies

Is NVST undervalued or overvalued?

NVST is slightly undervalued (as of the 2026-11-17 close). Discounting its cash flows at 8.5% (average of 3 methods) values the shares at $29.12; the price of $23.70 is 19% below that value, and 77% of that value comes from beyond year five.

What is the intrinsic value of NVST?

$29.12 per share (as of the 2026-11-17 close), against a market price of $23.70. That is a margin of safety of 18.6%. The value is the average of the 3 valuation methods that apply to this company, recomputed every night after the US close.